Abc-294640 clinical trials
Also written ABC294640 and Opaganib.
How each study uses abc-294640 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
RedHill Biopharma Limited (6) · Medical University of South Carolina (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses abc-294640 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaCompletedPhase 2/3RedHill Biopharma LimitedNCT04467840Written as Opaganib
- A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaCompletedPhase 2RedHill Biopharma LimitedNCT03377179Written as ABC294640
- A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular CarcinomaWithdrawnPhase 2Medical University of South CarolinaNCT02939807Written as ABC294640
- A Study of Opaganib in Coronavirus Disease 2019 PneumoniaCompletedPhase 2RedHill Biopharma LimitedNCT04414618Written as Opaganib
- ABC294640 (Opaganib) in Refractory / Relapsed Multiple MyelomaTerminatedPhase 1/2RedHill Biopharma LimitedNCT02757326Written as Opaganib
- Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring OxygenWithdrawnPhase 1/2RedHill Biopharma LimitedNCT04502069Written as Opaganib
- Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi SarcomaWithdrawnPhase 1/2RedHill Biopharma LimitedNCT02229981Written as ABC294640
Given beside what is tested · 1 — abc-294640 is usual care or a partner of the new treatment
Codes
What other systems call abc-294640 · ClinicalTrials.gg INT005602
- MeSH (NLM) C5487803-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DRG21OQ517OPAGANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27074100abc-294640Confirmed FDA, NLM, Wikidata
- DrugBank DB12764One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C548780 | 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DRG21OQ517 | OPAGANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074100 | abc-294640 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB12764 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.